Compare MOH & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | MDGL |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 11.5B |
| IPO Year | 2002 | 2005 |
| Metric | MOH | MDGL |
|---|---|---|
| Price | $196.74 | $471.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 19 |
| Target Price | $209.12 | ★ $682.11 |
| AVG Volume (30 Days) | ★ 547.3K | 223.1K |
| Earning Date | 10-21-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $45,426,000,000.00 | $180,133,000.00 |
| Revenue This Year | $2.05 | $59.37 |
| Revenue Next Year | $8.06 | $39.35 |
| P/E Ratio | $134.14 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $393.61 |
| 52 Week High | $244.89 | $615.00 |
| Indicator | MOH | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 27.69 |
| Support Level | $196.50 | $455.42 |
| Resistance Level | $204.11 | $546.29 |
| Average True Range (ATR) | 6.54 | 15.70 |
| MACD | 0.88 | -4.03 |
| Stochastic Oscillator | 73.00 | 13.66 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.